文献速递淋巴瘤

KEYNOTE-013 研究:帕博利珠单抗治疗经维布妥昔单抗治疗失败的经典霍奇金淋巴瘤的4年随访

KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure.
PubMed 文献 · Blood Adv · 2020-01-01

KEYNOTE-013 研究的经典霍奇金淋巴瘤独立扩展队列,纳入31例经维布妥昔单抗治疗失败或不适合/拒绝自体干细胞移植的患者,接受帕博利珠单抗 10 mg/kg 每2周静脉给药最长2年。中位随访52.8个月,完全缓解率19%,中位缓解持续时间未达到,36个月总生存率81%,未发生4级或5级治疗相关不良事件。

要点

  • 经维布妥昔单抗治疗失败的经典霍奇金淋巴瘤患者中,帕博利珠单抗完全缓解率为19%。
  • 中位随访52.8个月,中位缓解持续时间未达到,24个月和36个月缓解持续时间率均为50%。
  • 6例(19%)发生3级治疗相关不良事件,无4级或5级治疗相关不良事件。

核心结论

  • 在经重度既往治疗的经典霍奇金淋巴瘤队列中,长期随访显示帕博利珠单抗安全性良好,部分患者在治疗结束后数年仍维持长期缓解。

研究设计与样本

  • KEYNOTE-013 研究评估帕博利珠单抗单药治疗血液系统恶性肿瘤,经典霍奇金淋巴瘤为独立扩展队列,本报告为该队列中位随访超过4年的长期结果。
  • 纳入经自体干细胞移植后复发、不适合或拒绝自体干细胞移植,且经维布妥昔单抗治疗后进展或无应答的经典霍奇金淋巴瘤患者,共31例。
  • 患者接受帕博利珠单抗 10 mg/kg 每2周静脉给药,最长2年,或直至确认进展或不可接受毒性;主要终点为安全性和中心评估的完全缓解率。

主要发现

  • 入组患者既往接受中位5种治疗(范围2至15种)。
  • 中位随访52.8个月(范围7.0至57.6个月)时,完全缓解率为19%,中位缓解持续时间未达到;Kaplan-Meier法估算24个月和36个月缓解持续时间率均为50%。
  • 中位总生存期未达到,36个月总生存率为81%。
  • 6例患者(19%)发生3级治疗相关不良事件,无4级或5级治疗相关不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The KEYNOTE-013 study was conducted to evaluate pembrolizumab monotherapy in hematologic malignancies; classical Hodgkin lymphoma (cHL) was an independent expansion cohort. We present long-term results based on >4 years of median follow-up for the cHL cohort. The trial enrolled cHL patients who experienced relapse after, were ineligible for, or declined autologous stem cell transplantation and experienced progression with or did not respond to brentuximab vedotin. Patients received IV pembrolizumab 10 mg/kg every 2 weeks for up to 2 years or until confirmed progression or unacceptable toxicity. Primary end points were safety and complete response (CR) rate by central review. Enrolled patients (N = 31) had received a median of 5 therapies (range, 2 to 15). After a median follow-up of 52.8 months (range, 7.0 to 57.6 months), CR rate was 19%, and median duration of response (DOR) was not reached; 24-month and 36-month DOR rates were both 50% by the Kaplan-Meier method. Median overall survival was not reached; 36-month overall survival was 81%. Six patients (19%) experienced grade 3 treatment-related adverse events (AEs); there were no grade 4 or 5 treatment-related AEs. With long-term follow-up among a heavily pretreated cohort, pembrolizumab had a favorable safety profile; some patients maintained long-term response with pembrolizumab years after end of treatment. This trial was registered at www.clinicaltrials.gov as #NCT01953692.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Armand P, Kuruvilla J, Michot JM, et al. KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure. Blood Adv. 2020. PMID: 32556281. doi:10.1182/bloodadvances.2019001367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。